WeVote
Log In

Bill

Bill

RC 700

Para ordenar a la Comisión de Salud de la Cámara de Representantes de Puerto Rico realizar una urgente investigación exhaustiva en torno a la inclusión al diagnóstico y tratamiento de la condición de linfedema a la cubierta del Plan Vital y a planes privados; conocer los servicios cubiertos y no cubiertos por parte de todos los planes médicos; evaluar los altos costos asociados al diagnóstico de esta condición; así como auscultar la disponibilidad de terapias especializadas, equipos necesarios y el impacto de esta condición incapacitante en los pacientes que residen en Puerto Rico; y para otros fines relacionados.

2025-2028 Session

The bill orders an urgent investigation to determine how lymphedema is covered and accessed in Plan Vital and private plans, including services, costs, and equipment.

Referido a Comisión(es)
0
WeVote Research Nonpartisan
Bill Summary · RC 700

Overview

RC 700 (Session 2025-2028, Puerto Rico) seeks to order an urgent, exhaustive investigation by the Health Committee of the Puerto Rico House of Representatives. The investigation would examine the inclusion of lymphedema diagnosis and treatment in the Vital Plan (Plan Vital) and in private health plans, along with related services, costs, and availability of specialized therapies and equipment. The bill aims to inform related policy discussions and potential actions on access, coverage, and affordability for individuals with lymphedema in Puerto Rico.

Purpose and intent

  • Commission an urgent, comprehensive inquiry by the Health Committee to assess how lymphedema is addressed within public and private health coverage.
  • Determine what services related to lymphedema are covered or excluded by Plan Vital and by private health plans.
  • Evaluate the high costs associated with diagnosing and managing lymphedema.
  • Assess the availability of specialized therapies, necessary equipment, and the overall impact of lymphedema on patients residing in Puerto Rico.
  • Inform related policymaking and potential corrective actions or recommendations.

Key provisions and requirements (as currently described)

  • Tasking the Health Committee to conduct an exhaustive investigation with urgency.
  • Review of coverage: inclusion or exclusion of lymphedema diagnosis and treatment under Plan Vital and private plans.
  • Service mapping: identify which lymphedema-related services are covered and which are not across different plans.
  • Cost analysis: assess the financial burden and high costs associated with diagnosis and ongoing management.
  • Availability assessment: evaluate access to specialized therapies (e.g., lymph drainage, compression therapy, physical therapy), necessary medical equipment (e.g., compression garments, pumps), and the overall impact on patients’ daily lives and functioning.
  • Scope: focus on Puerto Rico residents and the real-world impact of coverage and access.

Affected parties and stakeholders

  • Patients with lymphedema in Puerto Rico and their families.
  • Enrollees in Plan Vital (the public health plan) and recipients of private health plans.
  • Healthcare providers specializing in lymphedema management (physical therapists, physicians, lymphedema specialists, medical equipment suppliers).
  • Puerto Rico Department of Health and relevant health policy bodies.
  • Legislators and the Health Committee, which would oversee and respond to findings.

Procedural and timeline aspects

  • Status: Radicado (filed) as of May 12, 2026.
  • The bill directs an urgent investigative process by the Health Committee, but does not specify a fixed completion date within the text provided. It implies expeditious handling given the term “urgente” (urgent) and the stated objective of informing related policy considerations.
  • Likely outcome pathways (not specified in text but typical for such measures): a formal report with findings and recommendations, potential proposed amendments to coverage policies, and guidance for administrative or regulatory actions.

Potential impacts and implications

  • Increased transparency: a clearer understanding of what lymphedema services are covered and at what cost.
  • Policy momentum: findings could prompt revisions to Plan Vital coverage or private plans, potentially expanding access to diagnosis, treatment, and essential equipment.
  • Patient access: identification of gaps may lead to advocacy for broader coverage of specialized therapies and necessary devices.
  • Cost considerations: the analysis could influence negotiations with providers and insurers regarding pricing, reimbursement, and affordability.
  • Health outcomes: improved access to appropriate diagnosis and treatment could positively affect quality of life and functional status for people with lymphedema in Puerto Rico.

Notes for readers

  • The bill focuses on an information-gathering and oversight role rather than creating existing coverage mandates. Depending on findings, it could pave the way for subsequent legislative or regulatory actions to improve lymphedema care in Puerto Rico.

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.